

iX BIOPHARMA SECURES SOUTH AFRICAN PATENT FOR WAFERIX DRUG DELIVERY TECHNOLOGY

Singapore, 21 November 2016 – Homegrown specialty pharmaceutical company **iX Biopharma Ltd.** (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a patent in South Africa (no. 2014/00310) for its **WaferiX** drug delivery technology. The patent will expire on 26 October 2030.

WaferiX is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream.

The WaferiX technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips, injections and oral intake. Key advantages of WaferiX include the reduction of the effect of first-pass metabolism, rapid onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.

iX Biopharma’s pipeline of products under development includes **Wafermine** and **BnoX** for pain management and **PheoniX** for erectile dysfunction. The market size for analgesics (drugs for pain management) in South Africa was approximately R2.9 billion (approximately S\$289 million) in 2015, according to Euromonitor International¹.

The grant of the South African patent comes close on the heels of the Canadian patent received last month and marks another milestone for iX Biopharma. To date, the Group has secured patents in nine countries, including Singapore, Australia, New Zealand, Malaysia, Indonesia, South Korea, Japan and Canada.

¹ Euromonitor International is a leading independent provider of strategic market research

About iX Biopharma Ltd

iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with manufacturing and laboratory testing facilities in Australia. The Group is focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health conditions. The Company leverages its patented sublingual drug delivery technology, **WaferiX**, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by regulatory bodies. Its pipeline of products under development includes **Wafermine** and **BnoX** for pain management, **PheoniX** for erectile dysfunction, and **WafeRest** for improved sleep quality.

Contact for media:

Ms Alvina Tan

DID: +65 6221 2123

H/P: +65 9787 7267

Email: alvina.tan@arkadvisors.com.sg

Ms Karin Lai

DID: +65 6221 0081

H/P: +65 9837 8136

Email: karin.lai@arkadvisors.com.sg

This document has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, CIMB Bank Berhad, Singapore Branch, for compliance with the relevant rules of the SGX-ST. CIMB Bank Berhad, Singapore Branch, has not independently verified the contents of this announcement. This document has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Tony Toh, Director, Investment Banking, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.